Plus Therapeutics
$1.38
22
-$0-0.22% Wednesday 20:00
Statistics
Day High
1.38
Day Low
1.32
52W High
2.78
52W Low
0.97
Volume
9,679
Avg. Volume
61,726
Mkt Cap
8.43M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Earnings
23OctExpected
Expected EPS
-0.5625
Actual EPS
N/A
People Also Follow
This list is based on the watchlists of people on Stock Events who follow PSTV. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Gritstone Bio
GRTS
Mkt Cap56.31M
Ayala Pharmaceuticals
ADXS
Mkt Cap851,880
Mustang Bio
MBIO
Mkt Cap10.47M
CRISPR Therapeutics
CRSP
Mkt Cap4.06B
Bluebird bio
BLUE
Mkt Cap108.22M
Fate Therapeutics
FATE
Mkt Cap417.93M
Allogene Therapeutics
ALLO
Mkt Cap549.96M
Analyst Ratings
14$Average Price Target
The highest estimate is $20.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%
About
Health Technology
Biotechnology
Manufacturing
Surgical and Medical Instrument Manufacturing
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Show more...
CEO
Marc Hedrick
Employees
20
Country
US
ISIN
US72941H4002